Bumper Offer - Urjas oil Just @ Rs. 1
Renvorab is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of Acidity. Renvorab also has some secondary and off-label uses. These are listed below.
The correct dosage of Renvorab depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. For detailed information on this, read through the dosage section.
Renvorab also has some side effects, the most common being Diarrhoea. Some other side effects of Renvorab have been listed ahead. These side effects of Renvorab are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Renvorab's effect during pregnancy is Safe and Moderate while nursing. Further, the section on Renvorab related warnings talks about Renvorab's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Diarrhea (Loose Motions) must refrain from the use of Renvorab since this can cause severe adverse effects. Other contraindications of Renvorab have been discussed in the sections ahead.
Besides this, Renvorab may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Renvorab is considered not safe while driving, and is not addictive.
Renvorab is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Renvorab is used -
Moderate
Mild
Common
Is the use of Renvorab safe for pregnant women?
Renvorab is safe to take during pregnancy.
Is the use of Renvorab safe during breastfeeding?
Breastfeeding women may feel side effects of Renvorab. If you see any side effects, stop taking Renvorab immediately and talk to your doctor. Take Renvorab again, only after your doctor's advice.
What is the effect of Renvorab on the Kidneys?
There are no side effects of Renvorab on the kidneys.
What is the effect of Renvorab on the Liver?
Renvorab may have mild side effects on the liver. Most people will never see any effect on the liver.
What is the effect of Renvorab on the Heart?
Using Renvorab does not have any harmful effects on the heart.
Renvorab should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Renvorab unless your doctor advises you to do so -
Is this Renvorab habit forming or addictive?
Forming a habit of Renvorab has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
After taking Renvorab, you should not drive or work on any heavy machine, as Renvorab can make you drowsy.
Is it safe?
There are no side effects of Renvorab, so it is safe for use.
Is it able to treat mental disorders?
There is no benefit of taking Renvorab for mental disorders.
Interaction between Food and Renvorab
You can take Renvorab with food.
Interaction between Alcohol and Renvorab
Taking alcohol with Renvorab can be dangerous.
Yes, Renvorab might lead to low magnesium levels in persons who take it for at least 3 months. Magnesium helps in absorption of vitamin D and calcium, low level of magnesium will affect the absorption of Vit. D and calcium lead to decrease bone density and increases the risk of bone fracture. Low-level magnesium can be managed by taking a dietary supplement which is rich in magnesium.
Yes, Renvorab may cause gas. It is a common side effect of this drug. If you experience excessive gas formation in the stomach after consuming this drug then inform to doctor right away without further delay.
Yes, Renvorab use is associated with the development of diarrhea. This might be related to an infection caused by Clostridium difficile. If you experience severe diarrhea after consuming this medicine, inform the doctor right away without further delay. In addition, one must take a lot of electrolytes and fluids for preventing dehydration. Taking an anti-diarrheal medication may also help.
Rarely, Renvorab causes hair loss. This is a reversible side effect of Renvorab, the problem goes away after discontinuation of this drug. For partial hair loss, you are advised to use hair tonic and discuss with your doctor about a better treatment option for hair loss.
This is because a long-term use of Renvorab can cause Vitamin B12 deficiency. Stomach acids help in the absorption of Vitamin B 12, and this drug suppresses stomach acid which is required for the absorption of vitamin B12. Hence patients taking [medicine] for a long time have Vitamin B12 deficiency. To replenish Vitamin B12 in your body your doctor prescribes this vitamin along with this medicine.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Aciphex® (rabeprazole sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 653
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1077-1078
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Aciphex® (rabeprazole sodium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 653
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1077-1078
